Immunic Q3 net loss $24.4M; positive ENSURE futility analysis; cash runway into Q3 2025

IMMUNIC, INC.

2024-Q3 EPS reported -$0.75

Net loss Q3 2024: $24.4M ($0.24/share) vs $22.8M ($0.51/share) in Q3 2023.
Cash $59.1M as of Sep 30, 2024; expected to fund operations into Q3 2025.
Phase 3 ENSURE futility analysis positive: IDMC recommends continuation without sample size increase.
Top-line data from Phase 2 CALLIPER (PMS) expected April 2025; ENSURE-1 completion Q2 2026.
New leadership: Jason Tardio appointed COO/President; Werner Gladdines promoted to CDO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.